Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
Trofinetide (DAYBUE)'s own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for Trofinetide (DAYBUE). Showing past 6 months and next 12 months · 3 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| Trofinetide (DAYBUE) | Neuren Pharmaceuticals | Peptide Therapeutic | Approved | 0 | ||||
| To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome | Biomed Industries, Inc. | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome | UCB BIOSCIENCES, Inc. | — | Phase 3 | — | — | — | — | — |
| A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome | Neurogene Inc. | — | Phase 3 | — | — | — | — | — |
| A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study) | Taysha Gene Therapies, Inc. | — | Phase 3 | — | — | — | — | — |
| Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome | Taysha Gene Therapies, Inc. | — | Phase 3 | — | — | — | — | — |
| Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome | Fenix Innovation Group | — | PHASE2/PHASE3 | — | — | — | — | — |
| Repurposing Mirtazapine in Rett Syndrome | University of Trieste | — | Phase 2 | — | — | — | — | — |
| A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome | Holland Bloorview Kids Rehabilitation Hospital | — | Phase 2 | — | — | — | — | — |
| Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT) | Fenix Innovation Group | — | PHASE1/PHASE2 | — | — | — | — | — |
| ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS) | Ionis Pharmaceuticals, Inc. | — | PHASE1/PHASE2 | — | — | — | — | — |
| Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study) | Taysha Gene Therapies, Inc. | — | PHASE1/PHASE2 | — | — | — | — | — |